119-30-2Relevant articles and documents
Iodination of aromatic compounds with iodine and n-butyltriphenylphosphonium peroxodisulfate
Tajik,Esmaeili,Mohammadpoor-Baltork,Ershadi,Tajmehri
, p. 1319 - 1323 (2003)
Iodine and n-butyltriphenylphosphonium peroxodisulfate can be successfully used for the iodination of some aromatic compounds in acetonitrile as solvent. The yields obtained are good to excellent.
Novel, water-based procedure for the mono iodination of aromatic amines and phenols
Sathiyapriya,Joel Karunakaran
, p. 1915 - 1917 (2006)
A mixture of potassium chlorate and potassium iodide was found to be a good iodinating agent for various aromatic amines and phenols with excellent yields in the presence of mineral acid in aqueous medium. Copyright Taylor & Francis Group, LLC.
Sulfated polyborate-H2O assisted tunable activation of N-iodosuccinimide for expeditious mono and diiodination of arenes
Misal, Balu,Palav, Amey,Ganwir, Prerna,Chaturbhuj, Ganesh
supporting information, (2021/05/26)
Owing to both Lewis and Bronsted acid active sites on sulfated polyborate under homogenous conditions, we were keen on developing iodination protocol of arenes that can meet the requirement of regioselectivity and higher yield. The sulfated polyborate activates N-iodosuccinimide for mono iodination of highly activated substrates viz. phenols, anilines under anhydrous condition. Water tunes sulfated polyborate to generate more Bronsted acid sites resulting in rapid activation of NIS for diiodination. The protocol was equally applicable to diiodination of 4-hydroxyphenylacetic acid to synthesize 4-hydroxy-3,5-diiodophenylacetic acid, an intermediate of tiratricol, a thyroid treatment drug. This protocol was further integrated via one-pot sequential iodination and Sonogashira coupling to synthesize aryl acetylenes, building blocks for the synthesis of a variety of specialty chemicals, API, and natural products.
HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF
-
Page/Page column 158, (2019/11/12)
Disclosed are HPK-1 inhibitors having a structure represented by Formula (X), pharmaceutical compositions comprising the HPK-1 inhibitors, methods of using the HPK-1 inhibitors, such as treating cancers, methods of preparing the HPK-1 inhibitors, and the synthetic intermediates.